# Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

> **NCT04640181** · PHASE2 · COMPLETED · sponsor: **St. David's HealthCare** · enrollment: 150 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT04640181
- **Lead sponsor:** St. David's HealthCare
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-06-28
- **Final completion:** 2021-06-28
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640181, "Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04640181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*